Restitutio ad integrum

Biocytogen to Present at BioJapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress

Retrieved on: 
Wednesday, September 28, 2022
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, GPCR, TNFR2, HKEX, ADC, Restitutio ad integrum, Patient, TCR, Medication, CD40, Research, Conference, PDAC, CCR8, Vaccine, Fine chemical

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) will host a seminar at the BioJapan2022 Conference on Friday, October 14.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) will host a seminar at the BioJapan2022 Conference on Friday, October 14.
  • Dr. Jie Xiang will outline the companys Project Integrum and antibody discovery capabilities at Biocytogen, including innovative animal models and preclinical pharmacology platform.
  • Finally, Dr. Yanan Guo will introduce the companys RenLite mouse and bispecific ADC platform.
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies.

Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-Based Cell Therapy

Retrieved on: 
Thursday, September 15, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Motherboard, Cancer, HKEX, Restitutio ad integrum, CMP, Sun Yat-sen University, HAP, Sun Yat-sen University Cancer Center, Antibody, HLA, Stock exchange, Immunotherapy, TCR, Patient, TDP, CEO, Cell, Medication, Research, MHC, University, GMP, TAL, TIL, Fine chemical, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (FineImmune) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (FineImmune) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens.
  • Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmunes unique cell therapy platform.
  • We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.
  • The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now.

Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy

Retrieved on: 
Thursday, September 15, 2022
Health, Science, Pharmaceutical, Research, Oncology, Motherboard, Cancer, HKEX, Restitutio ad integrum, CMP, Sun Yat-sen University, HAP, Sun Yat-sen University Cancer Center, Antibody, HLA, Mouse, Stock exchange, Immunotherapy, TCR, Patient, TDP, CEO, Cell, Medication, Research, MHC, University, GMP, TAL, TIL, Fine chemical, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (FineImmune) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (FineImmune) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens.
  • Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmunes unique cell therapy platform.
  • We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.
  • The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now.

Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs

Retrieved on: 
Thursday, September 1, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, GPCR, CEO, Technology, Research, Motherboard, Medication, Monoclonal antibody, Mouse, Global, PCCS, BeiGene, TRACON, Control, Pharmacology, HKEX, Stock exchange, Center for Drug Evaluation and Research, ADC, Hong Kong Stock Exchange, Local government, CD40, Drug discovery, TCR, Growth, Restitutio ad integrum, Vaccine, Fine chemical, Global Health Innovative Technology Fund

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the companys official listing on the Main Board of the Stock Exchange of Hong Kong.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the companys official listing on the Main Board of the Stock Exchange of Hong Kong.
  • The company harnesses these specialized models to provide preclinical pharmacology evaluation services for global pharmaceutical/biotech companies.
  • Biocytogen strives to become the headstream of novel antibody drugs.
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies.

Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs

Retrieved on: 
Thursday, September 1, 2022
Biotechnology, Pharmaceutical, Health, Other Health, GPCR, CEO, Technology, Research, Motherboard, Medication, Monoclonal antibody, Mouse, Global, PCCS, BeiGene, TRACON, Control, Pharmacology, HKEX, Stock exchange, Center for Drug Evaluation and Research, ADC, Hong Kong Stock Exchange, Local government, CD40, Drug discovery, TCR, Growth, Restitutio ad integrum, Vaccine, Fine chemical, Global Health Innovative Technology Fund

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the companys official listing on the Main Board of the Stock Exchange of Hong Kong.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the companys official listing on the Main Board of the Stock Exchange of Hong Kong.
  • The company harnesses these specialized models to provide preclinical pharmacology evaluation services for global pharmaceutical/biotech companies.
  • Biocytogen strives to become the headstream of novel antibody drugs.
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies.

US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

Retrieved on: 
Tuesday, August 30, 2022
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Lung cancer, Partnership, VP, Investigational New Drug, CEO, Safety, Leiomyosarcoma, Liposarcoma, Research, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immunoglobulin G, CD73, Medication, Doxorubicin, Sarcoma, ADCC, Ipilimumab, Food, Chondrosarcoma, TCON, PD-1, TRACON, Nasdaq, FDA, Therapy, CDC, Restitutio ad integrum, Trial of the century, Patient, CMO, Pharmaceutical industry, Fine chemical

As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy.

Key Points: 
  • As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy.
  • We are glad to learn that the combination therapy of YH001 + envafolimab and doxorubicin received IND approval by the FDA.
  • We look forward to enrolling patients in this study and giving patients additional options for their sarcoma treatment.
  • YH001 has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab.

US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

Retrieved on: 
Tuesday, August 30, 2022
Oncology, Health, FDA, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, Lung cancer, Partnership, VP, Investigational New Drug, CEO, Safety, Leiomyosarcoma, Liposarcoma, Research, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immunoglobulin G, CD73, Medication, Doxorubicin, Sarcoma, ADCC, Ipilimumab, Food, Chondrosarcoma, TCON, PD-1, TRACON, Nasdaq, FDA, Therapy, CDC, Restitutio ad integrum, Trial of the century, Patient, CMO, Pharmaceutical industry, Fine chemical

As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy.

Key Points: 
  • As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy.
  • We are glad to learn that the combination therapy of YH001 + envafolimab and doxorubicin received IND approval by the FDA.
  • We look forward to enrolling patients in this study and giving patients additional options for their sarcoma treatment.
  • YH001 has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab.

Industry Heavyweight Jason Volper Joins Integrum Worldwide as SVP of Creative

Retrieved on: 
Thursday, June 16, 2022
Momentum, Magnet, PBS, Solution, The Blue, Population, Real estate, Gold, Growth Enterprise Market, Eastern Fare Music Foundation, Restitutio ad integrum, Verizon (mobile network), Grand Central, Concert, American Express, Leadership, Operation Xcellerator, Marketing, Century 21 (real estate), VH1, SVP, History, LOS, Singani, Century, Radio, Organization, AOL, Lady Godiva, Industrial design, Tourism, Creative industries

LOS ANGELES , June 14, 2022 /PRNewswire/ -- Integrum Worldwide, the Apollo Capital Corp and M2B Growth Enterprises backed collective, today announced that creative heavyweight Jason Volper has joined the company as SVP of Creative. Volper adds to an exceptional leadership team that supports Integrum's two agencies Storia and Chalk and will be responsible for driving all creative initiatives across Integrum Worldwide's growing collective of agencies.

Key Points: 
  • LOS ANGELES, June 14, 2022 /PRNewswire/ -- Integrum Worldwide , the Apollo Capital Corp and M2B Growth Enterprises backed collective, today announced that creative heavyweight Jason Volper has joined the company as SVP of Creative.
  • Volper adds to an exceptional leadership team that supports Integrum's two agencies Storia and Chalk and will be responsible for driving all creative initiatives across Integrum Worldwide's growing collective of agencies.
  • Volper teams up with Integrum Worldwide after an extensive career working with some of the top brands and marketing agencies in the world.
  • Prior to Integrum, Volper co-founded his agency Ferocious Cow with then partner Rohan Caesar.

Marketing Industry Veteran Claude Zdanow Joins Integrum Worldwide as President

Retrieved on: 
Tuesday, June 14, 2022
Magnet, Pernod Ricard, Xbox, Name, Creative, Shell shock, PBS, Marketing, Chicago Symphony Orchestra, FX (TV channel), Restitutio ad integrum, CEO, Creativity, Solution, Music, Singani, Growth, Acquisition, Operation Xcellerator, Industry, Population, The Walt Disney Company, LOS, Growth Enterprise Market, The Recording Academy, Renewable energy, Management, Industrial design, Tourism, Zdanow, Eminem

LOS ANGELES, June 14, 2022 /PRNewswire/ -- Integrum Worldwide, the Apollo Capital Corp and M2B Growth Enterprises backed marketing agency collective, today announced that marketing industry veteran Claude Zdanow has joined as President. Zdanow adds to an exceptional leadership team that supports Integrum's two agencies Storia and Chalk and will be responsible for driving all future growth, continued scale, and global mergers and acquisitions for Integrum Worldwide's growing collective of agencies. 

Key Points: 
  • Zdanow brings a wide range of industry experience and an entrepreneurial spirit to Integrum Worldwide.
  • His role will be rooted in supporting the company's future growth, continued scale, and its global M&A strategy
    LOS ANGELES, June 14, 2022 /PRNewswire/ -- Integrum Worldwide , the Apollo Capital Corp and M2B Growth Enterprises backed marketing agency collective, today announced that marketing industry veteran Claude Zdanow has joined as President.
  • Integrum Worldwide operates as a platform that supports marketing agencies by centralizing key shared services and allowing the agencies to focus on what they do best.
  • Zdanow joins Integrum Worldwide following a period of scale and growth for the company.

Industry Leader Amy LaFrance Joins Integrum Worldwide as SVP of Client Development

Retrieved on: 
Thursday, June 9, 2022
Civic, Momentum, Magnet, The Coca-Cola Company, Marketing, Conagra Brands, PBS, Fortune 500, Johnson & Johnson, Growth, American Express, Cigna, Seagram, Restitutio ad integrum, Micrometre, Verizon (mobile network), Senior, Solution, Revlon, Singani, Omnicom Group, Operation Xcellerator, Escape, Population, GMR Marketing, LOS, AEP, Paul Lafrance, Fortune, Public relations, Lafrance

LOS ANGELES, June 9, 2022 /PRNewswire/ -- Integrum Worldwide, the Apollo Capital Corp and M2B Growth Enterprises backed collective, today announced that marketing leader Amy LaFrance has joined the company as Senior Vice President of Client Development. LaFrance adds to an exceptional leadership team that supports Integrum's two agencies Storia and Chalk and will be responsible for driving all client development and services across Integrum's growing collective of agencies.

Key Points: 
  • LOS ANGELES, June 9, 2022 /PRNewswire/ -- Integrum Worldwide , the Apollo Capital Corp and M2B Growth Enterprisesbacked collective, today announced that marketing leader Amy LaFrance has joined the company as Senior Vice President of Client Development.
  • LaFrance adds to an exceptional leadership team that supports Integrum's two agencies Storia and Chalk and will be responsible for driving all client development and services across Integrum's growing collective of agencies.
  • LaFrance teams up with Integrum Worldwide after an extensive career working at some of the top brands and marketing agencies in the world.
  • Prior to Integrum, LaFrance worked at Omnicom's GMR Marketing, leading award-winning experiential programming for Cigna, Seagram's Escapes, Micron and AEP.